KR102090181B1 - Anti-inflammatory composition comprising Cacalia firma extract as effective component - Google Patents

Abstract

The present invention is Byeongpungsam ( Cacalia firma ) relates to an anti-inflammatory composition containing an extract as an active ingredient, and the Byeongpungsam extract of the present invention has an excellent effect of inhibiting the production of NO induced by LPS, and thus is a health functional food for preventing or improving inflammation. , Functional cosmetics or can be used as a treatment for inflammation.

Description

Anti-inflammatory composition comprising Cacalia firma extract as effective component

The present invention is Byeongpungsam ( Cacalia firma ) relates to an anti-inflammatory composition containing an extract as an active ingredient, and more particularly, to an anti-inflammatory composition containing an extract of Byeongpungsam which can be used as a pharmaceutical, health functional food or cosmetic composition as an active ingredient. .

Inflammation is a normal defense mechanism of a living body that occurs when a person is injured by a physical wound or a microorganism. Through this inflammatory action, pathogens are neutralized or removed, and damaged tissue is repaired. Allows normal structure and function. Most diseases with inflammation result in a loss of quality of life such as tissue damage, pain and itching, and chronic inflammatory conditions include arthritis, asthma, multiple sclerosis of the brain and spinal cord, inflammatory bowel disease and atherosclerosis Causes Macrophages are the primary cells responsible for innate immunity, activated by numerous factors such as cytokines and bacterial lipopolysaccharide (LPS), and activated macrophages are nitric oxide (NO) and prostaglandin E ₂ It produces inflammatory factors such as (prostaglandin E ₂ , PGE ₂ ) as well as pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1 (IL-1). NO is a free radical, and is synthesized by nitric oxide synthase (NOS), and has three isoforms (eNOS (endothelial NOS), nNOS (neuronal NOS), and iNOS (inducible NOS)). isoform) (Cho et al. 2014. Biomol. Ther. 22: 288-294). Pro-inflammatory cytokines such as IL-1, TNF-α, and interferon-gamma can cause iNOS expression and NO production. Many malignant cancers such as brain cancer, breast cancer, lung cancer, prostate cancer, pancreatic cancer and melanoma are associated with iNOS expression, and excessive NO production can lead to epithelial cancer, mutations and DNA structure damage (Guo et al. 2012. J Agric. Food Chem. 60: 2157-2164).

On the other hand, Cacalia firma is a perennial herbaceous plant belonging to the family Chrysanthemum , which is a kind of large-sized plant called ‘ byeong-pung-byeong ’. The root leaves have long, round petioles, and have a heart-shaped shape with a diameter of 27-32 cm. The edges are divided into 11-15 pieces, and the forked pieces are triangular egg-shaped and irregularly serrated. Flowers bloom in June-August in yellowish-white colors, and shoots on the branches of the cone-shaped inflorescence, and the fruit has a light grayish-white feather. The plant has a unique scent, and young plants are eaten as herbs. At present, there have been few known cases of domestic and foreign research on Byeongpung Ssam, and research on efficacy is also insufficient.

Korean Registered Patent No. 1143980 discloses only a method of drying a broom sprout containing byeongpung scent (byeongpung ssam), and has not been disclosed about an anti-inflammatory composition containing the byeongpung ssam extract of the present invention as an active ingredient.

The present invention was derived by the above-mentioned needs, provides an anti-inflammatory composition containing the Byeongpungsam extract as an active ingredient, and the Byeongpungsam extract has an excellent effect of inhibiting the production of NO induced by LPS. By confirming that, the present invention was completed.

In order to solve the above problems, the present invention provides a health functional food composition for the prevention or improvement of inflammatory diseases containing Byeongpungsam extract as an active ingredient.

In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases containing Byeongpungsam extract as an active ingredient.

In addition, the present invention provides a cosmetic composition for preventing or improving inflammatory diseases containing Byeongpungsam extract as an active ingredient.

The present invention is Byeongpungsam ( Cacalia firma ) relates to an anti-inflammatory composition containing an extract as an active ingredient, and the Byeongpungsam extract of the present invention has an excellent effect of inhibiting the production of NO induced by LPS in RAW 264.7 cells, so the Byeongpungsam extract is an active ingredient The composition of the present invention containing as may be used as a material for preventing, improving or treating inflammation.

1 is a result of confirming the cell viability according to the concentration of Byeongpungsam extract. CON is an unprocessed negative control.
2 is a result of confirming the degree of NO production inhibition according to the treatment concentration of Byeongpungsam extract. LPS was treated to induce the production of NO.

The present invention is Byeongpungsam ( Cacalia firma ) It relates to a health functional food composition for preventing or improving inflammatory diseases containing an extract as an active ingredient.

In the health functional food composition according to an embodiment of the present invention, the solvent of the Byeongpungsam extract is C ₁ to C ₄ lower alcohol, water, or a mixture thereof, and preferably extracted using ethanol as a solvent, It is not limited to this.

The inflammatory disease is at least one inflammatory disease selected from arthritis, rhinitis, hepatitis, keratitis, gastritis, enteritis, nephritis, bronchitis, pleurisy, peritonitis, spondylitis, pancreatitis, urethritis, cystitis, burn inflammation, dermatitis, periodontitis, gingivitis and degenerative neuroinflammation It is preferable, but is not limited to this.

The health functional food composition of the present invention may be prepared in any one form selected from powder, granule, pill, tablet, capsule, candy, syrup, and beverage, but is not limited thereto.

When the health functional food composition of the present invention is used as a food additive, the health functional food composition may be added as it is or used with other foods or food ingredients, and may be suitably used according to a conventional method. The active ingredient may be appropriately used depending on the purpose of use (prevention or improvement). Generally, the health functional food composition of the present invention in the manufacture of a food or beverage is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less based on the raw material. However, in the case of long-term intake for health purposes, the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.

There are no particular restrictions on the type of the health functional food. Examples of foods to which the health functional food composition can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum products, dairy products including ice cream, various soups, beverages, tea Drinks, alcoholic beverages, and vitamin complexes are included and include all healthy foods in the ordinary sense.

In addition, the health functional food composition of the present invention may be prepared as a food, particularly a functional food. The functional food product of the present invention may include ingredients that are conventionally added. Examples include proteins, carbohydrates, fats, nutrients and seasonings. For example, when manufactured as a drink agent, natural carbohydrates or flavoring agents may be included as additional ingredients in addition to the active ingredient. The natural carbohydrates include monosaccharides (e.g. glucose, fructose, etc.), disaccharides (e.g. maltose, sucrose, etc.), oligosaccharides, polysaccharides (e.g. dextrins, cyclodextrins, etc.) or sugar alcohols (e.g. , Xylitol, sorbitol, erythritol, and the like). The flavoring agent may be a natural flavoring agent (eg, tau martin, stevia extract, etc.) and a synthetic flavoring agent (eg, saccharin, aspartame, etc.).

Various nutritional supplements, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonic acid, in addition to the above-mentioned health functional food composition It may further contain a carbonation agent used in the beverage. The proportion of the components to be added is not particularly important, but it is generally selected from the range of 0.01 to 0.1 parts by weight with respect to 100 parts by weight of the health functional food composition of the present invention.

In addition, the present invention is a bottle pungsam ( Cacalia firma ) relates to a pharmaceutical composition for the prevention or treatment of inflammatory diseases containing an extract as an active ingredient.

The pharmaceutical composition containing the Byeongpungsam extract according to the present invention is preferably a formulation of a cream, gel, patch, spray, ointment, warning agent, lotion, linen agent, pasta agent or cataplasma agent, but is not limited thereto.

In addition to the Byeongpung Ssam extract, it may further include a pharmaceutically acceptable carrier, excipient, or diluent, and as a carrier, excipient, or diluent that may be included in a pharmaceutical composition containing Byungpung Ssam extract, lactose, dextrose, sucrose , Oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate , Propyl hydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, it may be prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc., which are usually used.

The preferred dosage of the Byeongpungsam extract of the present invention depends on the patient's condition and body weight, the severity of the disease, the drug form, the route and duration of administration, and can be appropriately selected by those skilled in the art.

In addition, the present invention is a bottle pungsam ( Cacalia firma ) It relates to a cosmetic composition for preventing or improving inflammatory diseases containing an extract as an active ingredient.

The cosmetic composition may prevent or improve one or more skin inflammatory diseases selected from acute and chronic eczema, contact dermatitis, atopic dermatitis, seborrheic dermatitis, sun dermatitis, deprived dermatitis, papillary head, irritating dermatitis, mastocytosis or psoriasis. There is, but is not limited to this.

In the cosmetic composition according to an embodiment of the present invention, the cosmetic composition is a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion, It can be prepared with any one selected from foundation, wax foundation and spray, ointment for external skin, cream, softening lotion, nourishing lotion, pack, essence, hair tonic, shampoo, conditioner, hair conditioner, hair treatment, gel, Skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream, foundation, nutrition essence, sunscreen, soap, cleansing foam, cleansing lotion, It may have any one formulation selected from the group consisting of cleansing cream, body lotion and body cleanser, but is not limited thereto. The. The cosmetic composition composed of each of these formulations may contain various bases and additives necessary and appropriate for the formulation of the formulation, and the types and amounts of these components can be easily selected by those skilled in the art.

When the formulation of the cosmetic composition of the present invention is a paste, cream or gel, animal fibers, plant fibers, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide as carrier components Etc. can be used.

When the formulation of the cosmetic composition of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder can be used as a carrier component, and in the case of a spray, additionally, chlorofluorohydro Propellants such as carbon, propane-butane or dimethyl ether.

When the formulation of the cosmetic composition of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, and propylene Glycols, 1,3-butyl glycol oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan.

When the formulation of the cosmetic composition of the present invention is a suspension, a liquid diluent such as water, ethanol or propylene glycol as a carrier component, an ethoxylated isostearyl alcohol, a suspension agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or trakant, etc. can be used.

When the formulation of the cosmetic composition of the present invention is a surfactant-containing cleansing agent, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, acethionate, imidazolinium derivative, methyltaurate, sarcosinate as a carrier component , Fatty acid amide ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linoline derivatives or ethoxylated glycerol fatty acid esters and the like.

Hereinafter, the present invention will be described in more detail by using manufacturing examples and examples. It is obvious to those skilled in the art that these production examples and examples are only intended to illustrate the present invention more specifically and that the scope of the present invention is not limited by them.

Manufacturing example  One. Byeongpung Ssam  Preparation of extract

Byeongpungssam used in this experiment was purchased from Yangyang-si, Gyeongbuk, and 70% (v / v) ethanol 10 times the weight of Byeongpungssam was added and stirred for 10 hours at room temperature. Thereafter, the extract was centrifuged, the supernatant was filtered and concentrated, lyophilized, and then stored in a refrigerator and used as a sample for this experiment.

Example  One. Byeongpung Ssam  Confirmation of cell viability of extract

MTT (3- (4,5-dimeth-ylthiazol-2-) using the method of Mosmann (1983) to determine the effect of the Byeongpungsam extract of Preparation Example 1 on cell survival and to determine the range of concentrations to be used in the experiment yl) -2,5-diphenyltetrazolium bromide).

The mouse macrophage cell line RAW 264.7 cells were cultured in a 96-well plate containing 100 µl of DMEM medium for 1 day, and then cultured for 24 hours by treating the concentration-specific (50, 100 and 200 µg / ml) Byeongpungsam extract. Then, 10 μl of 5 mg / ml MTT solution was dispensed into each well, followed by incubation for 3 hours to induce a reduction reaction. 100 μl of DMSO (dimethyl sulfoxide) solution was added to form purple purple formazan (formazan) ) The crystal was completely dissolved. Thereafter, the absorbance at 570 nm was measured using a spectrophotometer, and the relative cell viability of the Byeongpungsam extract treated group was calculated based on 100% of the Bongpungsam extract untreated group. As a result, as shown in FIG. 1, it was found that the Byeongpungsam extracts according to the concentrations of Preparation Example 1 had little cytotoxicity because they did not significantly affect cell viability.

Example  2. Byeongpung Ssam  Of extract NO ( nitric oxide ) Check the inhibitory effect

To verify the anti-inflammatory effect, mouse macrophage cell line RAW 264.7 cells were inoculated in a 96-well plate to be 1 × 10 ⁶ cells / ml, and the temperature at 37 ° C. and 5% CO ₂ were maintained. Incubated in the incubator for 24 hours. After that, each well was treated with Byeongpungsam extract of Preparation Example 1 by concentration (50, 100 and 200 μg / ml) for 1 hour, after which 1 μg / ml LPS was treated and cultured for 24 hours. After cultivation, a supernatant of the culture solution was obtained, and the supernatant was reacted with a grease reagent, and absorbance was measured at a wavelength of 540 nm using a spectrophotometer. The NO production rate is expressed as a percentage of LPS.

As a result, as shown in FIG. 2, it was confirmed that the effect of inhibiting the production of NO induced by LPS in a concentration-dependent manner during the treatment of Byeongpungsam extract was confirmed.

Claims (7)

An anti-inflammatory health functional food composition containing 200 µg / ml of Cacalia firma 70% (v / v) ethanol extract as an active ingredient. delete delete delete delete delete A cosmetic composition for anti-inflammatory containing 200µg / ml of Cacalia firma 70% (v / v) ethanol extract as an active ingredient.

Images